Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Daniel P. Van Plew

The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $8,780,263 for Daniel P. Van Plew in fiscal 2025, including a base salary of $983,382. Disclosed compensation is on record for 9 fiscal years.

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Regeneron Pharmaceuticals, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Regeneron Pharmaceuticals, Inc. (REGN) $983,382 $8,780,263
2024 Regeneron Pharmaceuticals, Inc. (REGN) $964,100 $8,655,178
2023 Regeneron Pharmaceuticals, Inc. (REGN) $931,500 $8,760,149
2022 Regeneron Pharmaceuticals, Inc. (REGN) $900,000 $8,853,537
2021 Regeneron Pharmaceuticals, Inc. (REGN) $822,800 $8,774,090
2020 Regeneron Pharmaceuticals, Inc. (REGN) $825,577 $8,654,453
2019 Regeneron Pharmaceuticals, Inc. (REGN) $683,100 $7,829,513
2018 Regeneron Pharmaceuticals, Inc. (REGN) $660,000 $9,007,222
2017 Regeneron Pharmaceuticals, Inc. (REGN) $560,000 $8,978,600

Recent activity

No call appearances or filed executive changes recorded yet.